January 10, 2023Open Access

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

Key Points

Key points are not available for this paper at this time.

Abstract

antiviral resistance development may be predictive for the clinical situation. Therefore, our work will be important for the management of COVID-19 with Paxlovid and next-generation SARS-CoV-2 3CLpro inhibitors.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Dirk Jochmans

Liu C

Kim Donckers

Journals

mBio

Actions

Institutions

KU Leuven

University of Bern

Rega Institute for Medical Research

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study